BAG3’s Role in Indicating the Recurrence of TNBC

Abstract

Triple-negative breast cancer (TNBC) cells tend to resist chemotherapy drugs, making it essential to find other therapies
to treat this aggressive cancer. The inhibition of BAG3 with YM-1 is an option because BAG3 is overexpressed in over
50% of TNBC patients. BAG3 positively regulates the EGFR pathway and cell proliferation, which means inhibiting it
could reduce TNBC tumor size and lessen the recurrence of TNBC. This paper looks at xenografting BT-549 cell lines
in mice and treating them with docetaxel, PBS, and YM-1 at various concentrations. Changes in the tumor are tracked
using the tumor volume and weight of the mice. The results of this work will provide a better understanding of how
BAG3 inhibition impacts cell proliferation and whether it can be an indicator of TNBC recurrence. Studying YM-1
gives patients more options and the chance to find the best treatment.